Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2024
Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma.
Abstract readClinical Trial, Phase IIRandomized Controlled TrialMulticenter Study
In one paragraph
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Article
- The seventh kidney cancer research summit: progress in accelerating cures.The oncologist · 2026Article
- Papillary renal cell carcinoma with high-ABCC2 shows an immune-evasive profile associated with favorable response to immunotherapy.The Journal of pathology · 2026Article
- [Treatment options in rare urological tumors: potential of molecular tumor boards].Urologie (Heidelberg, Germany) · 2026Review
- Article
- Hong Kong Urological Association-Hong Kong Society of Uro-Oncology 2025 consensus on the management of locally advanced or metastatic renal cell carcinoma.Frontiers in oncology · 2026Review
- Real-life Use of Cabozantinib in Front-line therapy for Metastatic Renal Cell Carcinoma: The CabFRONT Study (Meet-URO 24).European urology open science · 2025Article
- Real-world assessment of clinical outcomes of first-line treatment in metastatic papillary renal cell carcinoma.The oncologist · 2025Article
- Current Evidences and Future Perspectives in the Management of Metastatic Non-Clear Cell Renal Cell Carcinoma.International journal of urology : official journal of the Japanese Urological Association · 2025Review
- Molecular Genetics of Renal Cell Carcinoma: A Narrative Review Focused on Clinical Relevance.Current oncology (Toronto, Ont.) · 2025Review
- STELLAR-304: a phase III study of zanzalintinib (XL092) plus nivolumab in advanced non-clear cell renal cell carcinoma.Future oncology (London, England) · 2025Article
- Targeting Heat Shock Transcription Factor 4 Enhances the Efficacy of Cabozantinib and Immune Checkpoint Inhibitors in Renal Cell Carcinoma.International journal of molecular sciences · 2025Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Pedro BarataUniversity Hospitals Seidman Cancer Center, Cleveland, OH.ORCID 0000-0002-8890-2951
Catherine TangenSWOG Statistics and Data Management Center, Seattle, WA.ORCID 0000-0001-8825-8660
Melissa PletsSWOG Statistics and Data Management Center, Seattle, WA.
Ian M ThompsonCHRISTUS Santa Rosa Medical Center Hospital, Houston, TX.
Vivek NarayanAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA.ORCID 0000-0002-8205-738X
Daniel J GeorgeDuke University Medical Center, Durham, NC.ORCID 0000-0003-1499-7203
Daniel Y C HengTom Baker Cancer Center, Calgary, AB, Canada.
Brian ShuchInstitute of Urologic Oncology, UCLA, Los Angeles, CA.ORCID 0000-0003-2065-3570
Mark SteinColumbia University, New York, NY.ORCID 0000-0002-0853-3640
Shuchi GulatiUC Davis Comprehensive Cancer Center, Sacramento, CA.ORCID 0000-0001-6793-9694
Maria TretiakovaUniversity of Washington, Seattle, WA.
Abhishek TripathiCity of Hope Comprehensive Cancer Center, Duarte, CA.ORCID 0000-0002-5198-0673
Georg A BjarnasonSunnybrook Odette Cancer Centre, Toronto, On, Canada.ORCID 0000-0001-6903-5357
Peter HumphreyYale School of Medicine, New Haven, CT.
Adebowale AdeniranYale School of Medicine, New Haven, CT.
Ulka VaishampayanUniversity of Michigan, Ann Arbor, MI.ORCID 0000-0001-5800-4571
Ajjai AlvaUniversity of Michigan, Ann Arbor, MI.
Tian ZhangUniversity of Texas Southwestern Medical Center, Dallas, TX.ORCID 0000-0001-8914-3531
Scott ColeOklahoma Cancer Specialists and Research Institute, Tulsa, OK.
Primo N LaraUC Davis Comprehensive Cancer Center, Sacramento, CA.ORCID 0000-0001-9512-0002
Seth P LernerBaylor College of Medicine, Houston, TX.ORCID 0000-0002-6379-2581
Naomi Balzer-HaasAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA.ORCID 0000-0001-8907-7968
Sumanta K PalCity of Hope Comprehensive Cancer Center, Duarte, CA.ORCID 0000-0002-1712-0848
Funding
NRG Oncology Network Group Operations Center - GY9 BIQSFP Reports/BudgetsU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI NORMAN WOLMARK · 2014 to 2026
$206.8MMember Site CoreU10CA180821 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Evanthia Galanis · 2014 to 2026
$177.3MProject-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · 2014 to 2026
$167.6MSWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PRIMO N. LARA · 2014 to 2026
$152.1MSWOG Statistics & Data Management Center complex - extension supplement for GY06U10CA180819 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Catherine M. Tangen · 2014 to 2026
$115.2MYale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MNCIC Clinical Trials Group - Canadian Collaborating Clinical Trials NetworkU10CA180863 · NCI · QUEEN'S UNIVERSITY AT KINGSTON · PI Janet Ellen Dancey · 2014 to 2026
$40.4MUM LAPs -UG1 GrantUG1CA233160 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ANNE F SCHOTT · 2019 to 2026
$5.4MCombination of Transcriptomic and Metallomic Biomarkers for Risk Assessment in Locoregional Clear Cell Renal Cell CarcinomaK08CA273542 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Shuchi Gulati · 2022 to 2026
$1.3MNCATS NIH HHS UL1 TR001863NCI NIH HHS K08 CA273542NCI NIH HHS U10 CA180819NCI NIH HHS U10 CA180820NCI NIH HHS U10 CA180821NCI NIH HHS U10 CA180863NCI NIH HHS U10 CA180868NCI NIH HHS U10 CA180888NCI NIH HHS UG1 CA233160
Abstract
PubMed holds no abstract for this paper.
Indexed as
Carcinoma, PapillaryCarcinoma, Renal CellCrizotinibKidney NeoplasmsPyridinesSunitinibTriazinesAdultAgedAged, 80 and overAnilidesAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansMaleMiddle Aged1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazineAnilidescabozantinibCrizotinibPyrazinesPyridinesSunitinibTriazines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.